No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PHAT Phathom Pharmaceuticals
- 9.180
- +0.080+0.88%
Close Apr 26 16:00 ET
- 8.900
- -0.280-3.05%
Post 16:38 ET
537.25MMarket Cap-2335P/E (TTM)
9.430High8.960Low370.89KVolume9.080Open9.100Pre Close3.40MTurnover0.86%Turnover RatioLossP/E (Static)58.52MShares17.01952wk High-7.39P/B397.17MFloat Cap6.06552wk Low--Dividend TTM43.26MShs Float64.540Historical High--Div YieldTTM5.17%Amplitude5.840Historical Low9.176Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Buy Rating Justified by Strong Market Acceptance of Phathom Pharmaceuticals' V Oquezna
SynOx Therapeutics Announces $75m Series B Round to Fund Phase 3 Trial of Potential Best-in-class Treatment for TGCT
SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a $75m...
13D Filings -- Barron's
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen
MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors -- Barrons.com
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen
12 Most Shorted Stocks in 2024
Buy Rating Affirmed for Phathom Pharmaceuticals Amid Strong Uptake of V Oquezna
Comments
$Phathom Pharmaceuticals(PHAT.US$ NEWS
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
SynOx Therapeutics has closed a $75m Series B financing round led by Forbion, HealthCap, and Bioqube Ventures to fund a Phase 3 trial of emactuzumab, a potential best-in-class treatment for Tenosynovial Giant Cell Tumour (TGCT). Emactuzumab has shown promising clinical activity with a 71% objective response rate and good tolerability in earl...
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
SynOx Therapeutics has closed a $75m Series B financing round led by Forbion, HealthCap, and Bioqube Ventures to fund a Phase 3 trial of emactuzumab, a potential best-in-class treatment for Tenosynovial Giant Cell Tumour (TGCT). Emactuzumab has shown promising clinical activity with a 71% objective response rate and good tolerability in earl...
2
may retest 6.60
$Phathom Pharmaceuticals(PHAT.US$ a high potential share..vonoprazan is a lot more effective than other ppi.
Insider share sales at Phathom Pharmaceuticals in the last three months are not substantial but still concerning. The level of insider ownership shows some alignment with smaller shareholders. However, 6 warning signs, 3 of which are concerning, should be noted by investors.
$Phathom Pharmaceuticals(PHAT.US$ wonder if breakout will continue to run
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg